[1] Booth G L, Kapral M K, Fung K, et al. Recent trends in cardiovascularcomplications among men and women with and without diabetes [J]. Diabetes Care, 2006, 29(1): 32-37.
[2] Haffner S J, Cassells H. Hyperglycemia as a cardiovascular risk factor [J]. Am J Med, 2003, 115(Suppl 8A): 6S-11S.
[3] McIntyre N, Holsworth D C, Turner D S. New interpretation of oral glucose tolerance [J]. Lancet, 1964, 2(7349): 20-21.
[4] Gautier J F, Fetita S, Sobngwi E, et al. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes[J]. Diabetes Metab, 2005, 31(3 Pt 1) : 233-242.
[5] 梁 霞, 闫振成. 胰高血糖素样肽-1在代谢性心血管病中的作用研究进展[J]. 解放军医学, 2014, 39(5): 425-428.
[6] Dailey M J, Moran T H. Glucagon-like peptide 1 and appetite [J].Trends Endocrinol Metab, 2013, 24: 85-91.
[7] ?rskov C, Poulsen S S, M?ller M,et al. Glucagon-like peptide I receptorsin the subfornical organ and the area postrema are accessible tocirculating glucagon-like peptide I[J]. Diabetes, 1996, 45: 832-835.
[8] Pannacciulli N, Bunt J C, Koska J, et al. Higher fastingplasma concentrations of glucagon-like peptide 1 are associated withhigher resting energy expenditure and fat oxidation rates in humans [J]. Am J Clin Nutr, 2006, 84: 556-560.
[9] Chang G, Zhang D, Yu H, et al. Cardioprotective effects of exenatide against oxidative stress-inducedinjury [J]. Int J Mol Med, 2013, 32(5):1011-1120.
[10] Saraiva F K, Sposito A C. Cardiovascular effects of Glucagon-like peptide 1(GLP-1) receptor agonists[J]. Cardiovasc Diabetol, 2014, 13:142-149.
[11] Moberly S P, Mather K J, Berwick Z C, et al. Impaired cardiometabolic responses to glucagon-likepeptide 1 in obesity and type 2 diabetes mellitus[J]. Basic Res Cardiol, 2013, 108(4): 365-369.
[12] Moberly S P, Berwick Z C, Kohr M, et al. Intracoronary glucagon-like peptide 1 preferentially augments glucoseuptake in ischemic myocardium independent of changes in coronary flow[J]. Exp Biol Med, 2012, 237(3): 334-342.
[13] Zhao T C. Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection [J]. Cardiovasc Diabetol, 2013, 12: 90.
[14] Sokos G G, Nikolaidis L A, Mankad S, et al. Glucagon-likepeptide-1 infusion improves left ventricular ejection fraction and functionalstatus in patients with chronic heart failure[J]. J Card Fail, 2006, 12(9): 694-699.
[15] Sokos G G, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting [J]. Am J Cardiol, 2007, 100(5): 824-829.
[16] Barragán J M, Rodríguez R E, Blázquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36 amide) in rats[J]. Am J Physiol, 1994, 266(3): E459-E466.
[17] Robinson L E, Holt T A, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis [J]. BMJ Open, 2013, 3(1): 1986.
[18] Edwards C M, Todd J F, Ghatei M A, et al. Subcutaneous glucagon-likepeptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemiain fasted healthy subjects[J]. ClinSci, 1998, 95(6): 719-724.
[19] Ceriello A, Novials A, Canivell S, et al. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes[J]. Diabetes Care, 2014, 37(7): 1938-1943.
[20] Erdogdu O, Nathanson D. Holm A, et al. Exendin-4stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requiresGLP-1 receptor[J]. Mol Cell Endocrinol, 2010, 325: 26-35.
[21] Wang D, Luo P, Wang Y, et al. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism[J]. Diabetes, 2013, 62(5):1697-1708.
[22] Batchuluun B, Inoguchi T, Sonoda N, et al. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway inhuman aortic endothelial cells[J]. Atherosclerosis, 2014, 232(1):156-164.
[23] Kelly A S, Richard M, Bergenstal R M, et al. Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial[J]. Cardiovasc Diabetol, 2012, 11: 64.
[24] Basu A, Charkoudian N, Schrage W, et al. Beneficial effects of GLP-1 on endothelial function in humans: dampening byglyburide but not by glimepiride[J]. Am J Physiol Endocrinol Metab, 2007, 293: E1289-E1295.
[25] Ceriello A, Esposito K, Testa R, et al. Thepossible protective role of glucagon-like peptide 1 on endotheliumduring the meal and evidence for an “endothelial resistance” toglucagon-like peptide 1 in diabetes[J]. Diabetes Care, 2011, 34: 697-702.
[26] Goto H, Nomiyama T, Mita T, et al. Exendin-4,a glucagon-like peptide-1 receptor agonist, reduces intimal thickeningafter vascular injury[J]. Biochem Biophys Res Commun, 2011, 405:79-84.
[27] Nagashima M, Watanabe T, Terasaki M, et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice[J]. Diabetologia, 2011, 54: 2649-2659.
[28] Tashiro Y, Sato K, Watanabe T, et al. A glucagon-like peptide-1 analog liraglutide suppressesmacrophage foam cell formation and atherosclerosis [J]. Peptides, 2014, 54: 19-26.
[29] Best J H, Hoogwerf B J, Herman W H, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospectiveanalysis of the life link database[J]. Diabetes Care, 2011, 34(1): 90-95.
[30] Nathanson D, Ullman B, L?fstr?m U, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlledclinical trial of efficacy and safety [J]. Diabetologia, 2012, 55(4): 926-935.
[31] Woo J S, Kim W, Ha S J, et al. Cardioprotective effects of exenatide in patients with ST-segment- elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study[J]. Arterioscler Thromb Vasc Biol, 2013, 33(9): 2252-2260.
[32] Hermansen K, B?kdal T A, Düring M, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial [J]. Diab Obesity Metabol, 2013, 15: 1040-1048.
[33] Baggio L L, Drucker D J. Biology of incretins: GLP-1 and GIP [J]. Gastroenterology, 2007, 132(6): 2131-2157.
[34] Marso S P, Daniels G H, Frandsen K B, et al. Liraglutide and cardiovascular outcomesin type 2 diabetes[J]. New Engl J Med, 2016,375(4):311-322.